Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer

NCT04607668 is registered in ClinicalTrials.gov with G1 Therapeutics, Inc. as lead sponsor.

NCT NCT04607668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04607668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Lead sponsor
G1 Therapeutics, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
January 6, 2021
Completion date
March 31, 2023
Enrollment
326 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapeutic toxicity, colorectal cancer metastatic, myelosuppression-adult